Results 251 to 260 of about 345,959 (307)
Tongluo Jiedu as an adjuvant therapy for oral cancer.
World J Clin CasesLomelí Martínez SM +2 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Breast Cancer, 2002
Recently, the guidelines for adjuvant hormonal therapy for primary breast cancer were presented at the National Institute of Health Consensus Development Conference in November 2000 and at the 7th International Conference on Adjuvant Therapy of Primary Breast Cancer in February 2001. Adjuvant hormonal therapy should be offered basically to all patients
Yasuhiro, Tamaki +2 more
openaire +2 more sources
Recently, the guidelines for adjuvant hormonal therapy for primary breast cancer were presented at the National Institute of Health Consensus Development Conference in November 2000 and at the 7th International Conference on Adjuvant Therapy of Primary Breast Cancer in February 2001. Adjuvant hormonal therapy should be offered basically to all patients
Yasuhiro, Tamaki +2 more
openaire +2 more sources
2009
This chapter focuses on the therapeutic strategies for patients with gliomas other than surgery (Chap. 6) and radiotherapy (Chap. 7). It deals with gliomas of all WHO grades and details the primary treatment as well as therapeutic options at recurrence.
Wick, W, Weller, M
openaire +2 more sources
This chapter focuses on the therapeutic strategies for patients with gliomas other than surgery (Chap. 6) and radiotherapy (Chap. 7). It deals with gliomas of all WHO grades and details the primary treatment as well as therapeutic options at recurrence.
Wick, W, Weller, M
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2014
Adjuvant therapy targets melanoma micrometastases in patients with surgically resected disease that carry a high risk of death from melanoma recurrence. In this setting, adjuvant therapy provides the greatest opportunity for cure before progression into advanced inoperable stages.
Ahmad A, Tarhini +1 more
openaire +2 more sources
Adjuvant therapy targets melanoma micrometastases in patients with surgically resected disease that carry a high risk of death from melanoma recurrence. In this setting, adjuvant therapy provides the greatest opportunity for cure before progression into advanced inoperable stages.
Ahmad A, Tarhini +1 more
openaire +2 more sources
Best Practice & Research Clinical Endocrinology & Metabolism, 2004
Endocrine therapy remains a cornerstone of systemic therapy for breast cancer even though it was first introduced more than a century ago. In the past three decades a large number of randomized trials involving several tens of thousands of patients have been performed to determine the role of endocrine therapy in the adjuvant setting.
openaire +2 more sources
Endocrine therapy remains a cornerstone of systemic therapy for breast cancer even though it was first introduced more than a century ago. In the past three decades a large number of randomized trials involving several tens of thousands of patients have been performed to determine the role of endocrine therapy in the adjuvant setting.
openaire +2 more sources
2018
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects.
Rena, Shah, Ruth M, O'Regan
openaire +2 more sources
The use of hormonal therapy in breast cancer has improved the overall outcome for patients with early-stage hormone receptor-positive disease. The choice of hormone therapy is related to multiple factors, including menopausal state, patient preference, and potential side effects.
Rena, Shah, Ruth M, O'Regan
openaire +2 more sources
Postoperative Adjuvant Therapy
Scandinavian Journal of Gastroenterology, 1988There is no proven significant benefit of adjuvant chemotherapy in colorectal cancer. Portal infusion of 5-FU in the immediate postoperative period has given some promising results but further trials of this treatment are necessary. Intraperitoneal administration should also be tested.
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2021
as adjuvant therapy for high-risk melanoma was extensively studied in regimens that varied by dosage, route of administration, formulation, and therapy duration. The high-dose regimen (HDI) showed significant improvements in relapse-free survival (RFS) in 3 trials and overall survival (OS) in 2.
openaire +2 more sources
as adjuvant therapy for high-risk melanoma was extensively studied in regimens that varied by dosage, route of administration, formulation, and therapy duration. The high-dose regimen (HDI) showed significant improvements in relapse-free survival (RFS) in 3 trials and overall survival (OS) in 2.
openaire +2 more sources